ForSight Robotics, an Israeli startup founded by Daniel Glozman, Joseph Nathan, and Moshe Shoham, is revolutionizing cataract surgery with its cutting-edge robotic platform, Oryom. With the aim of providing better and more cost-effective eye surgeries, the company recently raised $125 million in funding led by Eclipse Ventures, bringing its total investment to $195 million and valuing the company at an estimated $500 million.
The need for innovative solutions in cataract surgery is crucial, with over 4 million procedures performed annually in the United States alone. However, a shortage of eye doctors worldwide means that many individuals are unable to access the treatment they need. ForSight Robotics aims to bridge this gap by introducing robotics into the field of ophthalmology.
The company’s founders, who met at the Technion, Israel’s institute of technology, bring a wealth of expertise to the table. Moshe Shoham, a robotics expert, previously cofounded Mazor, a company focused on spine surgery that was acquired by Medtronic for $1.6 billion. Joseph Nathan, a surgeon, has experience in commercializing healthcare technology. Together with Daniel Glozman, an R&D expert, they launched ForSight Robotics in 2020.
ForSight’s robotic system combines microsurgical robots with computer vision and machine learning algorithms to perform high-precision eye surgeries. The company has conducted extensive testing on pig eyes, which closely resemble human eyes, and plans to perform its first full robotic surgery on a human patient later this year. By incorporating feedback from cataract surgeons, ForSight continues to refine its technology and design.
The potential impact of ForSight’s robotic platform is significant, especially in light of the global prevalence of preventable vision impairment and avoidable blindness. With more than 1 billion people worldwide affected by these conditions, the need for accessible and efficient eye surgeries is more pressing than ever.
Fred Moll, a pioneer of robotic surgery and a strategic advisor to ForSight Robotics, recognizes the potential of robotics in revolutionizing cataract surgery. He highlights the repetitive nature of the procedure and the precision required, making it an ideal candidate for robotic assistance.
As ForSight Robotics continues to gather clinical data and pursue regulatory approval in the U.S., the future of cataract surgery looks increasingly promising. By leveraging the latest advancements in robotics and healthcare technology, the company is poised to transform the field of ophthalmology and improve outcomes for millions of patients worldwide. In the coming years, Eclipse, a company specializing in robotic ophthalmic surgery, is poised to revolutionize the field of eye surgery. With sufficient funding to navigate the FDA approval process, Eclipse’s CEO, Nathan Winterroth, is confident in the company’s ability to bring their innovative technology to market.
In addition to seeking FDA approval, Eclipse has its sights set on commercializing its robotic surgery system in countries like India, where the demand for cataract surgery far exceeds the number of available surgeons. The company envisions a future where their robot can not only assist with cataract surgeries but also perform a range of other ophthalmologic procedures, including retina repairs, glaucoma treatments, and even rare and complex surgeries that few doctors are capable of.
Nathan emphasizes the importance of robotics in bridging the gap between the growing need for eye surgeries and the limited number of skilled surgeons available. He believes that automation is the key to increasing access to quality eye care on a global scale. As technology continues to advance, Nathan envisions Eclipse’s robotic system becoming an indispensable tool in the field of ophthalmology.
With a focus on innovation and accessibility, Eclipse is well-positioned to make a significant impact in the world of eye surgery. By harnessing the power of robotics, the company is paving the way for a future where advanced ophthalmic procedures are more widely available and efficiently performed. As Eclipse continues to push boundaries and break new ground, the future of eye surgery looks brighter than ever before.
